Loading company…
Sortera Bio develops drug discovery technology using its Deep Screening platform.
Sortera Bio's Deep Screening platform generates sequence-function datasets for AI-based drug discovery, including research on membrane proteins. The company works with biotechnology and pharmaceutical partners developing biologics. Based in Cambridge, UK, it raised GBP 7.5 mn in pre-seed funding in May 2024.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in